Acheson AG, Scholefield JH. Survival from cancers of the colon and rectum in England and Wales up to 2001. Br J Cancer. 2008;99(1):S33-4.

Article  PubMed  PubMed Central  Google Scholar 

Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, et al. Rectal cancer, version 2.2015. J Natl Compr Canc Netw. 2015;13:719–28.

Article  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

Article  PubMed  Google Scholar 

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.

Article  PubMed  Google Scholar 

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

Article  PubMed  Google Scholar 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

Article  PubMed  Google Scholar 

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

Article  PubMed  Google Scholar 

Yamaguchi Y, Hotta K, Imai K, Kakushma N, Ono H. Recurrence after curative surgical resection of T1 rectal cancer: a report of two cases. Dig Endosc. 2013;25(Suppl 2):26–30.

Article  PubMed  Google Scholar 

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–89.

Article  PubMed  Google Scholar 

Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016;35:939–51.

Article  CAS  PubMed  Google Scholar 

Zhang X, Hu F, Li G, Li G, Yang X, Liu L, et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis. 2018;9:25.

Article  PubMed  PubMed Central  Google Scholar 

Knüpfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients—a summary of published results. Int J Colorectal Dis. 2010;25:135–40.

Article  PubMed  Google Scholar 

Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008;68:323–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Serda M, Becker FG, Cleary M, Team RM, Holtermann H, et al. Synteza i aktywność biologiczna nowych analogów tiosemikarbazonowych chelatorów żelaza. Uniw śląski. 2013;7:343–54.

Google Scholar 

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (London, England). 2005;365:1054–61.

Article  CAS  PubMed  Google Scholar 

Du W, Hong J, Wang YC, Zhang YJ, Wang P, Su WY, et al. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway. J Cell Mol Med. 2012;16:1878–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003;101:2940–54.

Article  CAS  PubMed  Google Scholar 

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.

Article  CAS  PubMed  Google Scholar 

James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.

Article  CAS  PubMed  Google Scholar 

Van Etten RA. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med. 2007;204:461–5.

Article  PubMed  PubMed Central  Google Scholar 

Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535–40.

Article  CAS  PubMed  Google Scholar 

Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65:2662–7.

Article  CAS  PubMed  Google Scholar 

Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10:127–40.

Article  PubMed  Google Scholar 

Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–83.

Article  CAS  PubMed  Google Scholar 

Leroy E, Constantinescu SN. Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition. Leukemia. 2017;31:1023–38.

Article  CAS  PubMed  Google Scholar 

Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200.

Article  CAS  PubMed  Google Scholar 

Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14:1001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235–42. https://doi.org/10.1093/nar/28.1.235. PMID: 10592235; PMCID: PMC102472.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015;1263:243–50.

Article  CAS  PubMed  Google Scholar 

Yousaf A, Shehzadi T, Farooq A, Ilyas K. Protein active site prediction for early drug discovery and designing. Int Rev Appl Sci Eng. 2022;13:98–105.

Google Scholar 

Gschwen DA. Molecular docking towards drug discovery. J Mol Recogn. 1996. https://doi.org/10.1002/(SICI)1099-1352(199603)9:2%3c175::AID-JMR260%3e3.0.CO%3B2-D.

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Babu S, Nagarajan SK, Sathish S, Negi VS, Sohn H, Madhavan T. Identification of potent and selective JAK1 lead compounds through ligand-based drug design approaches. Front Pharmacol. 2022;13:837369.

Article  CAS  PubMed  PubMed Central